S. Li

944 citations

23 papers · 683 indexed · h-index 8

Impact in

Dermatology top 1%
- Dermatology and Skin Diseases
Immunology top 5%
- Psoriasis: Treatment and Pathogenesis

Papers in

Immunology 14
- Psoriasis: Treatment and Pathogenesis 13
- Immunodeficiency and Autoimmune Disorders 3
Hematology 6
- Autoimmune and Inflammatory Disorders Research 5

Co-authors: Yasmine Wasfi B. Randazzo Michael Song Tsen‐Fang Tsai L. Puig Susan Flavin Jingzhi Jiang Richard G. Langley
Journals: Annals of the Rheumatic Diseases (5 papers)British Journal of Dermatology (5 papers)Annals of Oncology (3 papers)BMJ Open (2 papers)Journal of the European Academy of Dermatology and Venereology (2 papers)
Partner nations: United States Canada China

In The Last Decade

S. Li

20 papers receiving 668 citations

Peers

Countries citing papers authored by S. Li

Since Specialization

Citations

This map shows the geographic impact of S. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Li more than expected).

Fields of papers citing papers by S. Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Li. The network helps show where S. Li may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Li Line = papers co-authored together S. Li links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma Frontiers in Immunology ·F. Buyens, Chenwei Zhang, Qingqing Shen, V. M. Yakimets, Javier Alfredo Carballo Perea, S. Li, Qianqian Yin, Yang Su-pin, Theresa Busse, Yu‐Hong Chen, Chenxi Xiang, Hui Liu	2025	1
2	Extensive perivascular spaces burden causally affects neurodegenerative diseases and brain structure: A two-sample bidirectional Mendelian randomization study Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Pei Wang, Xing-Mei Shu, S. Li, Xiaodong Han, Sasirekha Vijayakumar, Jin Gong, 淳司岡田, ZHENGWei-Qiang, Wolfgang Schwarz	2025	0
3	Structural and metabolic topological alterations associated with butylphthalide treatment in mild cognitive impairment: Data from a randomized, double‐blind, placebo‐controlled trial Psychiatry and Clinical Neurosciences ·Xiaodong Han, Zacarias Eduardo da Silva, Jin Gong, Pei Wang, Ruina Li, ZHENGWei-Qiang, Chang Xu, Sasirekha Vijayakumar, S. Li, Yufei Chen, Hayley Dunbar, Queensland, Obossou Achilles, C.B. Lucking, Sandra Sabu. T, J F Fravel	2025	0
4	Bibliometric analysis of neuroinflammation and Alzheimer’s disease Frontiers in Aging Neuroscience ·Sasirekha Vijayakumar, Jin Gong, S. Li, Pin Wang, Xiaodong Han, 博一黒阪, Queensland, Ruina Li, Obossou Achilles, Cuibai Wei	2024	5
5	Efficacy and safety of DL‐3‐n‐butylphthalide in patients with mild cognitive impairment: a multicentre, randomized, double‐blind, placebo‐controlled trial Alzheimer s & Dementia ·Pei Wang, Sasirekha Vijayakumar, Jin Gong, Xiaodong Han, Chang Xu, Yufei Chen, Franc Kljun, Queensland, S. Li, Ruina Li, Nobuo Obara, Sandra Sabu. T, Cuibai Wei	2024	0
6	Efficacy and safety of butylphthalide in patients with mild cognitive impairment: a multicentre, randomised, double-blind, placebo-controlled trial (EBMCI study) BMJ Open ·Pei Wang, Sasirekha Vijayakumar, Jin Gong, Xiaodong Han, Chang Xu, Yufei Chen, Hayley Dunbar, Queensland, S. Li, Ruina Li, Obossou Achilles, Sandra Sabu. T, J F Fravel	2024	2
7	Evaluation of safety and efficacy of intracranial self-expanding drug-eluting stents for symptomatic intracranial atherosclerotic stenosis: a prospective, multicentre, randomised controlled, superiority clinical trial protocol BMJ Open ·Zhiyuan Zhu, Yanyan He, Muh. Dian Firdausy, Wenbo Liu, 郭超美, S. Li, 邓书琴, В. В. Брель, Liangfu Zhu, Ziliang Wang, Tianxiao Li, Yingkun He	2024	1
8	632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT) Annals of Oncology ·Stéphane Oudard, Boris Hadaschik, Fred Saad, David Cella, Ethan Basch, Paul N. Mainwaring, Julie N. Graff, Shiva Dibaj, S. Li, И. А. Усенко, Peter De Porre, Jeremiah Trudeau, Eric J. Small, Mitchell R. Smith	2020	3
9	451 Association between HLA-Cw6 status and response to guselkumab in patients with moderate to severe plaque psoriasis Journal of Investigative Dermatology ·PÂMELA ISADORA SCHUMANN, Samuel E. DePrimo, Silviu E. Rogobete, S. Li, Ernesto J. Muñoz‐Elías	2018	4
10	Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies British Journal of Dermatology ·Kristian Reich, Kim Papp, April W. Armstrong, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, B. Randazzo, Michael Song, Alexa B. Kimball	2018	53
11	LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO) Annals of Oncology ·Nobuaki Matsubara, K.N. Chi, Mustafa Özgüroğlu, A. Rodrı́guez-Antolı́n, Susan Feyerabend, Luis Fein, B. Yа. Alekseev, Comunidad Seri, Andrew Protheroe, S. Li, Suneel Mundle, Peter De Porre, NamPhuong Tran, K. Fazazi	2018	4
12	Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial British Journal of Dermatology ·Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Yasmine Wasfi, Jingzhi Jiang, S. Li, L. Puig	2017	245
13	Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR) British Journal of Dermatology ·Andrew Blauvelt, Laura K. Ferris, Paul S. Yamauchi, Abrar A. Qureshi, C. Leonardi, Kamyar Farahi, Steven Fakharzadeh, Ming-Chun Hsu, S. Li, Marc Chévrier, Kevin S. Smith, Kavitha Goyal, Yanqing Chen, Ernesto J. Muñoz‐Elías, Kristina Callis Duffin	2017	45
14	SAT0563 Long Term Improvements in Physical Function are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients Annals of the Rheumatic Diseases ·Arthur Kavanaugh, L. Puig, Alice B. Gottlieb, Christopher T. Ritchlin, S. Li, Yin You, Alan M. Mendelsohn, Michael Song, Proton Rahman, Iain B. McInnes	2015	2
15	THU0419 Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-Up from the Psoriatic Arthritis Clinical Development Program Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Iain B. McInnes, Christopher T. Ritchlin, Proton Rahman, L. Puig, Alice B. Gottlieb, Michael Song, B. Randazzo, S. Li, Yin You, Alan M. Mendelsohn	2015	2
16	SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Iain B. McInnes, Alice B. Gottlieb, L. Puig, Proton Rahman, Christopher T. Ritchlin, S. Li, А. А. Самоленко, Mittie K. Doyle, Johannes Augustinus Los	2013	1
17	The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection British Journal of Dermatology ·Tsen‐Fang Tsai, Vincent Ho, Michael Song, Philippe Szapary, Takeshi Kato, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, C. Leonardi, (unknown), (unknown)	2012	65
18	Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study Journal of the European Academy of Dermatology and Venereology ·Alexa B. Kimball, Kim Papp, Yasmine Wasfi, Daphne Chan, Robert Bissonnette, Howard Sofen, Newman Yeilding, S. Li, Philippe Szapary, Kenneth B. Gordon, (unknown)	2012	162
19	The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Annals of Oncology ·Ethan Basch, Charles J. Ryan, Thian Kheoh, Karim Fizazi, C. Logothetis, Dana E. Rathkopf, Mitchell R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas W. Griffin, S. Li, Michael L. Meyers, A. Molina, Charles S. Cleeland	2012	2
20	OP0158 Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled psummit I study Annals of the Rheumatic Diseases ·Iain B. McInnes, Arthur Kavanaugh, A.B. Gottlieb, L. Puig, Proton Rahman, Christopher T. Ritchlin, S. Li, А. А. Самоленко, Alan M. Mendelsohn, Mittie K. Doyle	2012	17

About S. Li

S. Li is a scholar working on Immunology, Hematology, Neurology, Dermatology and Biological Psychiatry, having authored 23 papers that have together received 683 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (13 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Dermatology and Skin Diseases (4 papers), Rheumatoid Arthritis Research and Therapies (4 papers), Neurological Disease Mechanisms and Treatments (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers), Prostate Cancer Treatment and Research (3 papers) and Pharmaceutical studies and practices (3 papers). The work is most often cited by research in Dermatology (338 citations), Immunology (593 citations), Hematology (111 citations), Rheumatology (118 citations) and Physiology (139 citations). S. Li has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Yasmine Wasfi, B. Randazzo, Michael Song, Tsen‐Fang Tsai, L. Puig, Susan Flavin, Jingzhi Jiang, Richard G. Langley, Kim Papp and Alexa B. Kimball. Their work appears in journals such as Annals of the Rheumatic Diseases, British Journal of Dermatology, Annals of Oncology, BMJ Open and Journal of the European Academy of Dermatology and Venereology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact